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Antibody structure in protected and unprotected regions before and after cleaving 
agent treatment using the Hydrazide method. 
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Antibody structure in protected and unprotected regions before and 
after cleaving agent treatment using the Aldehyde (Schiff base) method. 
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Effect of support pore size on the percentage of Fab regions retained. 
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Effect of support pore size on the percentage of Fab regions remaining 
following cleaving agent treatment. 
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Effect of time on the amount of retained antibody remaining after 
cleaving agent treatment. 
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Retention of fluorescein or fluorescein-BSA by an anti-fluorescein 
restricted access media. 
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Percent extraction of fluorescein or fluorescein by an anti-fluorescein 
restricted access media. 
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Restricted access media with protected and unbound protein. 
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Amount of Human Serum Albumin retained using a hydrazide-activated 
support with pore sizes ranging from 50 A to 1000 A. 
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1. 
RESTRICTED ACCESSMEDIA AND 
METHODS FOR MAKING RESTRICTED 
ACCESSMEDIA 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
This application claims the benefit of U.S. Provisional 
Patent Application No. 61/092,546 filed Aug. 28, 2008 under 
35 USC 119(e) and incorporated herein by reference in its 
entirety. 
STATEMENT REGARDING FEDERALLY 
SPONSORED RESEARCH ORDEVELOPMENT 
GOVERNMENTAL SUPPORT 
This invention was made with Government support under 
Grant #R01 GMO44931 and Grant #R01 DKO69629, both 
awarded by the National Institutes of Health. The government 
has certain rights to this invention. 
BACKGROUND OF THE INVENTION 
Restricted access media (RAM) have been used for many 
years in work with biological samples to combine the features 
of size exclusion chromatography with partition or ion-ex 
change chromatography. The Support in RAM is typically 
porous silica or a porous polymer having a non-adsorptive 
and hydrophilic outer Surface and an interior stationary phase 
that can retain analytes through partitioning or ionic interac 
tions. This provides a medium in which only low mass Sub 
stances are retained, while larger agents such as proteins elute 
in the excluded volume. RAM have been used for analysis of 
drugs, peptides, and endogenous Substances in complex 
samples such as serum, blood, urine, and cell cultures. 
Many Small molecules Such as drugs and hormones bind 
proteins and/or other agents that are present in a sample. This 
gives rise to both a free (non-bound) form and a bound form 
of the small molecule in the sample. Traditional methods for 
separating free and bound forms of Small molecules include 
equilibrium dialysis and ultrafiltration, which can involve 
long analysis times, are often labor intensive, and usually 
require additional analytical methods for actual measurement 
of the free form. These methods involve a size separation 
between the free form and bound form. Non-affinity 
restricted access media columns have been used for separa 
tion of free and bound forms, however, these columns have 
given only partial separation and work for only some ana 
lytes. Ultrafast extraction of free forms by small immobilized 
antibody columns have been reported, however, these assays 
require using an antibody Support that can recognize and bind 
the free form without having significant interactions with the 
bound form. Accordingly, a need exists for a media having 
high selectivity towards free forms of the small molecule but 
without significant interactions with bound forms and meth 
ods for making these media. 
One challenge presented by immobilized or covalently 
linked molecules is to attach them to supports while retaining 
their behavior in their native form. Covalently linking or 
immobilization of molecules directly to the Support may 
affect the molecule's activity if the molecule is linked at or 
near its active site. For example, antibodies attached to a 
Support by their F, fragment may decrease and/or lose their 
ability to bind antigen. Covalent immobilization may also 
result in multisite attachment and random orientation of the 
molecule, which often leads to decreased or complete loss of 
activity. Noncovalent immobilization techniques can involve 
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the adsorption of a ligand binding agent to a surface, the 
binding of one ligand binding agent to a second ligand bind 
ing agent, or the formation of a complex between the ligand 
binding agent and Support. Entrapment or encapsulation tech 
niques involve the physical containment of a molecule in a 
support. Previously described entrapment methods are lim 
ited to particular types of Supports (i.e., Sol gels) and are 
useful only with relatively small Volume systems (i.e., capil 
lary columns in HPLC). Accordingly, a need exists for non 
covalent retention of molecules that is applicable to a variety 
of different Support materials and molecules to produce Sup 
ports containing noncovalently linked agents that closely 
mimic the behavior of these same agents in their native 
unbound form. 
SUMMARY OF THE INVENTION 
The invention generally relates to Restricted Access Media 
that comprise protected ligand binding agents or enzymes and 
methods of making Such Restricted Access Media Supports. 
In certain embodiments, the present invention provides new 
RAM supports and methods for making RAM supports. In 
one aspect, the RAM Supports contain covalently bound 
ligand binding agent molecules in protected regions. Another 
aspect provides methods for preparing a restricted access 
media containing covalently bound ligand binding agent mol 
ecules in protected regions. In another aspect, the RAM Sup 
ports contain unbound ligand binding agent or enzyme mol 
ecules retained by a capping agent. A further aspect provides 
methods for preparing a restricted access media containing 
unbound ligand binding agent or enzyme molecules retained 
by a capping agent. 
In certain embodiments, the invention provides a restricted 
access media comprising a Support wherein a plurality of 
protected regions of said Support contain one or more 
covalently linked ligand binding agent molecule(s) and 
wherein a plurality of unprotected regions of said Support 
contain one or more covalently linked blocking agent mol 
ecule(s). In certain embodiments, the Support can comprise 
an inorganic material, a biological material, an organic mate 
rial, an organic polymer, a composite Support, or a modified 
Support. In certain embodiments, the Support can comprise 
silica, glass, alumina, Zirconia, silver, gold, agarose, dextran, 
cellulose, polystyrene, polymethacrylate, polyamide, agar 
ose-coated quartz, agarose-coated stainless steel, or coated 
polystyrene/divinylbenzene. In certain embodiments, the 
ligand binding agent molecule can comprise a protein, a 
glycoprotein, a DNA, a RNA, a nucleoprotein, or a carbohy 
drate containing agent. In certain embodiments, the blocking 
agent molecule can comprise a Sub-fragment of the ligand 
binding agent molecule wherein ligand binding activity is 
reduced or eliminated. In certain embodiments, the blocking 
agent molecule can also comprise a Sub-fragment of a linking 
agent. In certain embodiments, the linking agent can com 
prise a carbohydrate, a nucleic acid, or a peptide. 
In certain embodiments, the invention provides methods 
for preparing a restricted access media comprising incubating 
an activated Support with a solution comprising a plurality of 
ligand binding agent molecules to form a ligand bound Sup 
port wherein the ligand binding agent molecule is covalently 
linked to the Support; treating the ligand bound Support with 
a size restricted cleaving agent that cleaves one or more ligand 
binding agent molecule(s) or one or more linking agent mol 
ecules bound to unprotected regions of the Support; and 
removing the cleaving agent and unbound fragments of 
cleaved ligand binding agent molecules or linking agent mol 
ecules, thereby preparing a restricted access media. In certain 
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embodiments, the Support can comprise silica, glass, alu 
mina, Zirconia, silver, gold, agarose, dextran, cellulose, poly 
styrene, polymethacrylate, polyamide, agarose-coated 
quartz, agarose-coated Stainless Steel, or coated polystyrene? 
divinylbenzene. In certain embodiments, the Support can 
comprise a pore size in the range of about 50 A to about 500 
A. In certain embodiments, the size restricted cleaving agent 
can comprise an enzyme or ribozyme. In certain embodi 
ments, the ligand binding agent molecule can comprise a 
protein, a glycoprotein, a DNA, a RNA, a nucleoprotein, or a 
carbohydrate containing agent. In certain embodiments, the 
ligand binding agent molecule can be covalently linked to the 
Support by an amine group, a sulfhydryl group, a carboxylate 
group, a carbonyl group, or a combination thereof. In certain 
embodiments, the ligand binding agent molecule can further 
comprise an activated ligand binding agent molecule. In cer 
tain embodiments, the linking agent can comprise a protein, a 
glycoprotein, a DNA, a RNA, a nucleoprotein, or a carbohy 
drate containing agent. In certain embodiments, the size 
restricted cleaving agent can comprise a protease. In certain 
embodiments, the protease can comprise a cysteine protease, 
a serine protease, a threonine protease, an aspartate protease, 
or a metalloprotease. In certain embodiments, the activated 
Support can be activated by an aldehyde or a hydrazide. 
In certain embodiments, the invention provides restricted 
access media comprising a Support wherein a plurality of 
protected regions of the Support contain one or more unbound 
ligand binding agent(s) or enzyme molecules and wherein the 
ligand binding agent(s) or enzyme molecule(s) are retained in 
the protected regions by a capping agent. In certain embodi 
ments, the protected region of the Support can be on a surface, 
in an interior pore, or a combination thereof. In certain 
embodiments, the Support can comprise an inorganic mate 
rial, a biological material, an organic material, an organic 
polymer, a composite Support, or a modified Support. In cer 
tain embodiments, the Support can comprise silica, glass, 
alumina, Zirconia, silver, gold, agarose, dextran, cellulose, 
polystyrene, polymethacrylate, polyamide, agarose-coated 
quartz, agarose-coated Stainless Steel, or coated polystyrene? 
divinylbenzene. In certain embodiments, the unbound ligand 
binding agent can comprise a protein, a glycoprotein, a DNA, 
a RNA, a nucleoprotein, a carbohydrate containing agent, a 
lipoprotein, or a combination thereof. In certain embodi 
ments, the capping agent can comprise a glycoprotein, a 
glycolipid, a carbohydrate containing agent, or a combination 
thereof. In certain embodiments, the carbohydrate containing 
agent can comprise glycogen, dextran, agarose, or cellulose. 
In certain embodiments, the invention provides methods 
for preparing a restricted access media comprising incubating 
an activated Support with a solution comprising: i) a ligand 
binding agent or an enzyme molecule and ii) an activated 
capping agent; and removing unbound capping agent from 
said incubated Support, thereby preparing the restricted 
access media comprising a Support wherein a plurality of 
protected regions of said support contain one or more 
unbound ligand binding agent(s) or enzyme molecule(s) and 
wherein said ligand binding agent(s) or enzyme molecule(s) 
are retained in said protected regions by said capping agent. In 
certain embodiments, the method can further comprise wash 
ing the restricted access media with a solution to deactivate 
bound capping agent. In certain embodiments, the Solution to 
deactivate bound capping agent can comprise a hydrazide 
containing agent or an amine-containing agent. In certain 
embodiments, the protected region of the activated Support is 
on a surface, in an interior pore, or a combination thereof. In 
certain embodiments, the ligand binding agent or the enzyme 
molecule and the activated capping agent can be incubated 
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together with the activated Support or incubated separately 
with the activated Support. In certain embodiments, the acti 
vated Support can comprise silica, glass, alumina, Zirconia, 
silver, gold, agarose, dextran, cellulose, polystyrene, poly 
methacrylate, polyamide, agarose-coated quartz, agarose 
coated stainless steel, or coated polystyrene? divinylbenzene. 
In certain embodiments, the activated Support can be acti 
vated by a hydrazide group, an amine group, an aldehyde 
group, or a combination thereof. In certain embodiments, the 
activated capping agent can comprise a glycoprotein, a gly 
colipid, or a carbohydrate-containing agent. In certain 
embodiments, the carbohydrate containing agent can com 
prises glycogen, dextran, agarose, or cellulose. In certain 
embodiments, the activated capping agent can be activated by 
oxidization with an oxidizing agent. In certain embodiments, 
the oxidizing agent comprises a periodate, a periodate-related 
chemical, or an enzyme treatment. In certain embodiments, 
the activated capping agent can comprise an oxidized capping 
agent, a hydrazide-containing agent, an amine-containing 
agent, or hydrazine. In certain embodiments, the Support can 
comprise a porous support with a pore size of about 50 A to 
about 1000A. In certain embodiments, the enzyme molecule 
can comprise an oxidoreductase, a transferase, a hydrolase, a 
lyase, an isomerase, or a ligase. 
In certain embodiments, the invention provides kits for 
preparing a restricted access media comprising: i) a Support 
that is Substantially free of ligand binding agent molecules 
and ii) a size restricted cleaving agent. In certain embodi 
ments, the kits can further comprise any one of: 1) instruc 
tions for the use thereof, 2) a solution for activating the 
Support, 3) an activated Support, 4) a ligand binding agent 
molecule that is not covalently linked to the support or a 
linking agent that is not covalently linked to the Support; or 
any combination of elements 1, 2, 3, and/or 4. In certain 
embodiments of any of the foregoing kit embodiments, the 
restricted access media that is prepared comprises a Support 
wherein a plurality of protected regions of said support con 
tain one or more covalently linked ligand binding agent mol 
ecules and wherein a plurality of unprotected regions of said 
Support contain one or more covalently linked blocking agent 
molecule(s). 
In certain embodiments, the invention provides kits com 
prising restricted access media comprising: i) a Support 
wherein a plurality of protected regions of the Support contain 
one or more covalently linked ligand binding agent molecules 
and wherein a plurality of unprotected regions of the Support 
contain one or more covalently linked blocking agent mol 
ecule(s) and ii) at least one container. In certain embodiments, 
the kits can further comprise instructions for the use thereof. 
In certain embodiments, the invention provides kits for 
preparing a restricted access media comprising: i) a Support 
that is Substantially free of ligand binding agent or enzyme 
molecules, and ii) a capping agent. In certain embodiments, 
the kits can further comprise any one of: 1) a solution for 
activating the capping agent; 2) a Solution for activating said 
support; 3) instructions for the use thereof; 4) an activated 
Support; 5) aligand binding agent oran enzyme molecule that 
is not associated with the Support; or any combination of 
elements 1,2,3,4, and/or 5. In certain embodiments of any of 
the foregoing kit embodiments, the restricted access media 
that is prepared can comprise a Support wherein a plurality of 
protected regions of the Support contain one or more unbound 
ligand binding agent(s) or enzyme molecule(s) and wherein 
the ligand binding agent(s) or enzyme molecule(s) are 
retained in the protected regions by a capping agent. 
In certain embodiments, the invention provides kits com 
prising a restricted access media comprising: i) a Support 
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wherein a plurality of protected regions of the Support contain 
one or more unbound ligand binding agent or enzyme mol 
ecules and wherein the ligand binding agent(s) or enzyme 
molecules are retained in the protected regions by a capping 
agent, and ii) at least one container. In certain embodiments, 
the kits can further comprise instructions for the use thereof. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 is an illustration showing the preparation of a 
Restricted Access Medium. 
FIG. 2 is an illustration showing the structure of antibodies 
located in protected and unprotected regions of the Support 
before and after enzyme treatment for (a) the hydrazide 
activated Support method and (b) the aldehyde-activated Sup 
port method. 
FIG. 3 is an illustration showing the structure of an IgG 
antibody before and after papain or pepsin treatment. 
FIG. 4(a) is bar graph showing the amount of covalently 
linked antibody versus nominal pore size of the Support 
before and after cleaving agent treatment. 
FIG. 4(b) is bar graph showing the percentage of F, 
regions remaining versus nominal pore size of the Support. 
FIG. 5 is a line graph showing the amount of antibody 
remaining after cleaving agent treatment. 
FIG. 6 is a line graph showing the effect of cleaving agent 
concentration on the amount of F, and antibody remaining 
following treatment with cleaving agent. 
FIG. 7 are chromatograms showing (a) fluorescein reten 
tion by an anti-fluorescein RAM column and a control col 
umn and (b) fluorescein-bovine serum albumin (BSA) reten 
tion by an anti-fluorescein RAM column and a control 
column. 
FIG. 8 shows the percent extraction of fluorescein or fluo 
rescein-BSA by an anti-fluorescein RAM. 
FIG. 9 is an illustration showing (a) reaction between oxi 
dized glycogen as the capping agent and a hydrazide-acti 
vated Support and (b) retention of a protein as oxidized gly 
cogen as the capping agent reacts with the hydrazide 
activated Support. 
FIG. 10 is a graph showing the amount of human serum 
albumin (HSA) retained using a hydrazide-activated Support 
with pore sizes ranging from 50 A to 1000 A. 
DETAILED DESCRIPTION 
Definitions 
As used herein, the phrase “ligand binding agent 
molecule(s) refers to one or more molecules that can seques 
ter another molecule or “target” from a solution. Ligand bind 
ing agent molecules include, but are not limited to, a protein, 
a glycoprotein, a DNA, a RNA, a nucleoprotein, or a carbo 
hydrate-containing agent. 
The terms “protein,” “peptide.” and “polypeptide' are used 
interchangeably herein to refer to a polymer of amino acid 
residues of any length. 
As used herein, the phrase “blocking agent molecule(s) 
refers to a molecule that is covalently linked to a support to 
create a protected region in or upon the Support. A blocking 
agent molecule can include, but is not limited to, a cleaved 
Sub-fragment of a ligand binding agent molecule resulting 
from treatment with a cleaving agent, leaving only a Sub 
fragment of the ligand binding agent molecule covalently 
linked to a Support. In certain embodiments, the Sub-fragment 
of the ligand binding agent molecule that is linked to the 
Support following cleavage is a Sub-fragment where ligand 
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binding activity is reduced. In certain embodiments, the Sub 
fragment of the ligand binding agent molecule that is linked to 
the Support following cleavage is a Sub-fragment where 
ligand binding activity is eliminated. In still other embodi 
ments, the Sub-fragment of the ligand binding agent molecule 
that is linked to the Support following cleavage is a Sub 
fragment wherealigand binding domain has been removed or 
has been disrupted. In certain embodiments, the Sub-fragment 
of the ligand binding agent molecule that is linked to the 
Support following cleavage can be further modified using a 
chemical reagent or second binding agent to reduce non 
specific binding. In other embodiments, a blocking agent 
molecule can be a different molecule than the ligand binding 
agent molecule. In certain embodiments where the blocking 
agent molecule is different than the ligand binding agent 
molecule, the blocking agent molecule can be a Sub-fragment 
of a linking agent. As used herein, a “linking agent” refers to 
a molecule that is conjugated to the ligand binding agent 
molecule and is used to attach the ligand binding agent mol 
ecule to the Support. Linking agents include, but are not 
limited to, carbohydrates, nucleic acids, and peptides. 
As used herein, the phrase “capping agent” refers to a 
molecule that is used to retain an unbound ligand binding 
agent or enzyme in a protected region. 
As used herein, the phrase “protected region” refers to an 
area or space of a Support that contains either one or more 
ligand binding agent molecule(s) or enzyme molecules Such 
that access to the contained molecules is restricted to mol 
ecules within a desired molecular weight range. A "protected 
region' includes, but is not limited to, a pore, a space, a gap, 
an opening, a hole, a crack, a fissure, a cavity, a pit, a crater, a 
cleft, a crevice, or combinations thereof. 
As used herein, the phrase “unprotected region” refers to 
an area or space of a Support that is large enough to be 
accessible by a cleaving agent. In the context of a RAM media 
comprising one or more covalently linked ligand binding 
agent molecule(s) in a protected region, a region occupied by 
one or more blocking agent molecule(s) following enzyme or 
protease treatment would represent an “unprotected region.” 
In the case where the ligand binding agent molecule is an 
antibody that is covalently linked to the support by its F. 
region, for example, the cleaved F portion of the antibody 
molecule that remains following cleaving agent treatment 
resides in an “unprotected region'. 
As used herein, the phrases “covalently linked and “cova 
lent linkage” mean attached by a covalent bond. For example, 
an antibody can be covalently linked to an aldehyde-activated 
Support by amine linkages between the antibody and the 
aldehyde-activated Support. 
As used herein, the term "conjugated” means joined 
together. Conjugation includes covalent linkages. For 
example, a linking agent can be conjugated to, or joined 
together with, a ligand binding agent molecule. 
As used herein, the phrase “substantially free' refers to a 
composition wherein the undesired material is present at a 
final percent (i.e. weight undesired material/total composi 
tion weight) of at least less than about 1%. 
Restricted Access Media Comprising Protected Covalently 
Linked Ligand Binding Agents 
Certain embodiments of the invention include restricted 
access media comprising a Support wherein a plurality of 
protected regions of the Support contain one or more 
covalently linked ligand binding agent molecule(s) and 
wherein a plurality of unprotected regions of the Support 
contain one or more covalently linked blocking agent mol 
ecule(s). The Support can be any Support that can be used 
directly or in a modified form for ligand binding agent attach 
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ment and combinations thereof. In certain embodiments, Sup 
ports can comprise an inorganic Support material. Inorganic 
Support materials can include, but are not limited to, silica, 
glass, alumina, Zirconia, silver, and gold. In certain embodi 
ments, Supports can comprise a biological Support material. 
Biological Support materials can include, but are not limited 
to, agarose, dextran, and cellulose. Supports can comprise 
one or more organic Support material(s) and organic polymer 
Supports. Organic Support materials and organic polymer 
Supports can include, but are not limited to, polystyrene, 
polymethacrylate, and polyamide. In other embodiments, the 
Support can comprise a composite Support. Composite Sup 
ports include, but are not limited to, an agarose coating on 
quartz, an agarose coating on stainless steel, and coated poly 
styrene/divinylbenzene. In other embodiments, the support 
can comprise a modified Support. Modified Supports can 
include, but are not limited to, silica, glass beads, polystyrene, 
gold, or silver that contain an added chemical group. Chemi 
cal groups used in modified Supports include, but are not 
limited to, Surface diol groups, aldehyde groups, hydrazide 
groups, amine groups, and Sulfhydryl groups. Formats for the 
Support can comprise porous or non-porous particles, planar 
surfaces, or flow-through supports. Other formats for the 
Support can include, but are not limited to, monolithic mate 
rials or perfusion Supports, membrane Supports, capillaries, 
fibers, and expanded bed Supports. 
The ligand binding agent molecule can be a protein, a 
glycoprotein, a DNA, a RNA, a nucleoprotein, or a carbohy 
drate-containing agent. Without seeking to be limited by 
theory, a size-restricted cleaving agent, such as an enzyme, 
protease, or other agent, is unable to access the ligand binding 
agent molecule residing in protected regions. While again not 
seeking to be limited by theory, access of the size restricted 
cleaving agent can be restricted by electrostatic and/or steric 
hindrance. Thus, the size restricted cleaving agent cannot 
cleave the ligand binding agent molecule, leaving it 
uncleaved or intact. For example, the ligand binding agent 
molecule can be an antibody. As shown in FIG. 1(a) using an 
IgG antibody as the ligand binding agent molecule, the anti 
body is covalently linked to the support by the F regions. 
Upon treatment with an enzyme capable of cleaving away F, 
regions, the enzyme is inaccessible to the antibody 
molecule(s) residing in protected regions or excluded from 
the protected regions. Thus, the enzyme or protease cannot 
cleave antibody molecules residing in the protected regions, 
leaving those molecules uncleaved or intact. 
A blocking agent molecule can be a Sub-fragment of the 
ligand binding agent molecule. The blocking agent molecule 
can also be a Sub-fragment of a linking agent. In certain 
embodiments, a linking agent is conjugated to the ligand 
binding agent molecule and is used to attach the ligand bind 
ing agent molecule to the Support. Linking agents include, but 
are not limited to, carbohydrates, nucleic acids, and peptides. 
In an exemplary embodiment, a nucleic acid linking agent 
can be conjugated to a ligand binding agent that can be a 
protein, a carbohydrate, or another nucleic acid. The nucleic 
acid linking agent—ligand binding agent conjugate can then 
be covalently linked to the support by the nucleic acid linking 
agent. The nucleic acid is then cleaved with a size restricted 
cleaving agent. The size restricted cleaving agent can be, for 
example, an enzyme such as a nuclease. When the ligand 
binding agent is also a nucleic acid, the nuclease can in certain 
embodiments be a site specific nuclease that selectively 
cleaves the nucleic acid linking agent. In this embodiment, 
the remaining Sub-fragment of the nucleic acid that is linked 
to the Support following nuclease cleavage is the blocking 
agent. 
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In another exemplary embodiment, a carbohydrate linking 
agent can be conjugated to a ligand binding agent that can be 
a protein or a nucleic acid. The carbohydrate protein con 
jugate can then be covalently linked to the Support by the 
carbohydrate linking agent. The carbohydrate is then cleaved 
by a size restricted cleaving agent. The size restricted cleav 
ing agent can be, for example, an enzyme that cleaves the 
carbohydrate. In this embodiment, the remaining Sub-frag 
ment of the carbohydrate linking agent that is linked to the 
Support following cleavage is the blocking agent. 
In yet another exemplary embodiment, a peptide linking 
agent can be conjugated to the ligand binding agent that can 
be a nucleic acid, a carbohydrate, or another protein. The 
peptide linking agent—ligand binding agent conjugate can 
then be covalently linked to the support by the peptide linking 
agent. The peptide is then cleaved with a size restricted cleav 
ing agent. The size restricted cleaving agent can be, for 
example, a protease or peptidase. When the ligand binding 
agent is also a protein, the protease or peptidase can in certain 
embodiments be a site specific protease or peptidase that 
selectively cleaves the peptide linking agent. In this embodi 
ment, the remaining Sub-fragment of the peptide that is linked 
to the Support following cleavage is the blocking agent. 
As described, the ligand binding agent can be attached 
either directly to the support or can be attached to the support 
with a linking agent. Without seeking to be limited by theory, 
the size restricted cleaving agent is able to access the ligand 
binding agent molecule or linking agent residing in or on 
unprotected regions and that is linked either directly or 
through a linking agent to the unprotected regions of the 
Support. Thus, the size restricted cleaving agent cleaves the 
ligand binding agent molecule or linking agent. The sub 
fragment of the cleaved ligand binding agent or linking agent 
that is covalently linked to the support forms the blocking 
agent molecule(s), whereby the fragment of the cleaved 
ligand binding agent or linking agent—ligand binding agent 
conjugate that is not covalently linked or is otherwise 
unbound to the Support is removed. As shown in the non 
limiting and exemplary embodiment depicted in FIG. 1(a). 
when using an IgG antibody as the ligand binding agent 
molecule, the antibody can be covalently linked to the support 
by the F regions. Upon treatment with an enzyme capable of 
cleaving away F, regions, the F. Sub-fragments of the anti 
body are cleaved from the antibody molecules residing in or 
on unprotected regions of the Support. The F region of the 
antibody molecule that is covalently linked to the support 
remains following enzyme treatment and forms the blocking 
agent molecule. 
Methods for Preparing a Restricted Access Media Compris 
ing Protected Covalently Linked Ligand Binding Agents 
Other embodiments of the invention include methods for 
preparing a restricted access media. Methods provided herein 
comprise incubating an activated Support with a solution hav 
ing a plurality of ligand binding agent molecules to form a 
ligand bound Support wherein the ligand binding agent mol 
ecule is covalently linked to the support. The ligand bound 
Support is treated with a size restricted cleaving agent that 
cleaves one or more ligand binding agent molecule(s) bound 
to unprotected regions of the Support. The cleaving agent and 
unbound fragments of cleaved ligand binding agent mol 
ecules are removed, thereby preparing the restricted access 
media. 
The ligand binding agent molecule can be a protein, a 
glycoprotein, a DNA, a RNA, a nucleoprotein, or a carbohy 
drate-containing agent. The ligand binding agent molecule 
can be, for example, an antibody. Alternatively, the ligand 
binding agent can be an aptamer or a lectin. 
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The ligand binding agent molecule(s) can be covalently 
linked to the Support by an amine group, a Sulfhydryl group, 
a carboxylate group, a carbonyl group, or a combination 
thereof. The ligand binding agent molecule(s) can also be 
activated prior to incubation with the Support. For example, a 
ligand binding agent molecule having carbohydrate residues 
can be activated by oxidization of the carbohydrate residues. 
Activation by oxidization can be performed by treatment of 
the ligand binding agent molecule(s) with periodic acid, a 
periodate-related chemical, or an enzyme treatment. In other 
embodiments, the plurality of ligand binding agent molecules 
can comprise ligand binding agent molecules that are conju 
gated linking agents. In this embodiment, ligand binding 
agent molecules can be covalently linked to the Support by a 
linking agent. Linking agents can be carbohydrates, nucleic 
acids, and peptides that can be attached to the Support. 
The activated Support used in the method can be any Sup 
port that can be used directly or in a modified form for ligand 
binding agent attachment and combinations thereof. The Sup 
port can be, for example, inorganic Support materials. Inor 
ganic Support materials can be, for example, silica, glass, 
alumina, Zirconia, silver, and gold. The Support also can be 
biological Support materials. Biological Support materials 
can be, for example, agarose, dextran, and cellulose. The 
Support further can be organic Support materials and organic 
polymer Supports. Organic Support materials and organic 
polymer Supports can be, for example, polystyrene, poly 
methacrylate, and polyamide. The Support can be composite 
Supports. Composite Supports can be, for example, agarose 
coating on quartz, agarose coating on stainless steel, and 
coated polystyrene? divinylbenzene. Modified supports can 
be, for example, silica, glass beads, polystyrene, gold, or 
silver that contain, for example, Surface diol groups, aldehyde 
groups, hydrazide groups, amine groups, and Sulfhydryl 
groups. Formats for the Support can comprise porous or non 
porous particles, planar Surfaces, or flow-through Supports. 
Other formats for the support can include, but are not limited 
to, monolithic materials or perfusion Supports, membrane 
Supports, capillaries, fibers, and expanded bed Supports. An 
activated Support can be an aldehyde-activated Support or a 
hydrazide-activated Support. 
An aldehyde-activated Support can be prepared according 
to a method adapted from Larsson (104 Methods Enzymol. 
212-223 (1984)) and Ruhn et al., (669 J. Chromatogr. 9-19 
(1994)). Briefly, for example, an aldehyde-activated support 
can be prepared by treating a porous silica Support with a 
Solution comprising an organic silane Such as, 3-glycidox 
ypropyltrimethoxysilane, to introduce epoxy groups onto the 
Support. The resulting epoxy groups are hydrolyzed by treat 
ing the Support with a sodium acetate Solution. After washing 
with water, the Support is treated with an aqueous Solution of 
Sulfuric acid to convert epoxy groups to diol groups. The 
resulting diol support is treated with a solution of 90% (v/v) 
acetic acid and water containing 500 mg periodic acid and 
mixed for about two hours at room temperature to convert diol 
groups to aldehyde groups. The resulting aldehyde-activated 
support is washed with water followed by washing with a 
potassium phosphate buffer and stored until use. 
To prepare a hydrazide-activated Support, an aldehyde 
activated Support is treated with a potassium phosphate buffer 
containing about a 5-fold mole excess of Oxalic dihydrazide 
(calculated using the initial diol groups present in the added 
Support) with shaking for about 2 hours at room temperature. 
After several potassium phosphate buffer washes, about a 
25-fold mole excess (calculated using the initial diol groups) 
of sodium borohydride in 0.1 M potassium phosphate buff 
ered saline (PBS) is added in small portions to the slurry and 
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incubated with shaking for about 90 minutes at room tem 
perature to reduce any remaining aldehyde groups. The Sup 
port is Subsequently washed in potassium phosphate buffer 
and stored until use. 
To form the ligand bound support wherein the ligand bind 
ing agent molecule is covalently linked to the Support, an 
activated Support is treated with a solution comprising a 
ligand binding agent molecule(s) to form a slurry. The 
amount of ligand binding agent molecule(s) used can be 
greater than the maximum amount that can be immobilized 
on the Surface of the Support and based on the Surface area of 
the Support and size of the ligand binding agent molecule(s). 
For example, if the ligand binding agent molecule is an IgG 
antibody, the amount used is about two-fold greater than the 
maximum amount that can be immobilized to the Surface of 
the support, as determined by Clarket al., (888.J. Chromatog. 
13-22 (2000)) and by calculations based on the known surface 
area of the support and size of IgG (see e.g., Walters etal. (140 
Anal. Biochem. 190-195 (2000)). When an aldehyde-acti 
vated Support is used, a solution Such as an 8 mg/mL Sodium 
cyanoborohydride solution, can be added to the slurry to 
promote formation of stable secondary amine linkages 
between the ligand binding agent molecule(s) and the Sup 
port. When a hydrazide-activated Support is used, the ligand 
binding agent molecule can be activated prior to addition to 
the Support. When the ligand binding agent molecule is an 
IgG antibody for example, the antibody can be activated by 
oxidization with periodate to generate aldehyde groups in the 
carbohydrate regions. Preferably, cross-linked or precipitated 
immunoglobulins are removed from the final oxidized anti 
body solution prior to incubation with the activated support. 
The activated support and ligand binding agent molecule 
slurry is incubated while shaking for 3 days at 4°C. The 
resulting Support is washed with about 0.1 M potassium phos 
phate buffer (pH 8.0) and treated with a 4 mg/mL solution of 
sodium borohydride for about 90 minutes at room tempera 
ture to convert any remaining aldehyde groups into alcohols. 
A ligand bound Support obtained by any of the methods 
provided herein or elsewhere is treated with a size restricted 
cleaving agent to produce the restricted access media in 
which protected regions of the Support contain uncleaved 
ligand binding agent molecule(s) and unprotected regions of 
the Support contain cleaved ligand binding agent molecule(s). 
Without seeking to be limited by theory, some of the ligand 
binding agent molecule(s) within protected regions of the 
support will be inaccessible to the cleaving agent. This will 
leave ligand binding agent molecules residing in protected 
regions intact, while ligand binding agent molecules residing 
in unprotected regions of the support will be cleaved. For 
example, using an IgG antibody as the ligand binding agent 
molecule and an enzyme capable of cleaving away Fab 
regions as the cleaving agent, antibody molecules residing in 
unprotected regions are accessible to the enzyme and are 
cleaved. Antibodies residing in protected regions, however, 
are inaccessible to the enzyme and remain intact where they 
can function to bind their target molecule (see, FIGS. 1(a) and 
(b)). FIG. 2(b) is an illustration showing the structure of an 
IgG antibody covalently linked to an aldehyde-activated Sup 
port using the Schiff base method before and after cleaving 
agent treatment. Antibody molecules residing within a pro 
tected region Such as a pore remain intact following cleaving 
agent treatment. Antibody molecules residing in an unpro 
tected region Such as an outer Surface, are cleaved. Depending 
on where the covalent linkage between the antibody molecule 
and the Support occurs, either the F, or F. Sub-fragment 
remains covalently attached to the Support following cleaving 
agent treatment. In FIG. 2(b), the cleaved sub-fragments rep 
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resenting the F, and F regions of the antibody form the 
blocking agent molecule(s). FIG. 2(a) is an illustration show 
ing the structure of an IgG antibody covalently linked to a 
hydrazide-activated Support before and after cleaving agent 
treatment. Antibody molecules residing within a protected 
region Such as a pore remain intact following cleaving agent 
treatment. Antibody molecules residing in an unprotected 
region Such as an outer Surface, are cleaved. Because the 
antibody molecule is covalently linked to the hydrazide-acti 
vated Support by the F region, only the Sub-fragment repre 
senting the Fregion remains covalently linked to the Support 
and forms the blocking agent molecule(s) in this illustration. 
The size restricted cleaving agent can be a lyase or hydro 
lase. For example, the size restricted cleaving agent can be an 
enzyme or ribozyme. The size restricted cleaving agent can 
also be, for example, a protease (also referred to herein inter 
changeably with the term "peptidase). Proteases that can be 
used include, but are not limited to, cysteine proteases, serine 
proteases, threonine proteases, aspartate proteases, and met 
alloproteases. Proteases that can be used as size restricted 
cleaving agents can also include, but are not limited to, 
trypsin, elastase, papain, pepsin, ficin, Lys-C, or Glu-C. 
Several criteria can be considered when selecting the size 
restricted cleaving agent. In certain embodiments, a size 
restricted cleaving agent able to digest the ligand binding 
agent molecule at well-defined sites and that leaves the bind 
ing regions largely intact can be used. In certain embodi 
ments, a size restricted cleaving agent that cleaves the ligand 
binding agent molecule into only a few large fragments can be 
used. The size restricted cleaving agent should also be large 
enough that it is excluded from the protected regions of the 
support such that ligand binding agent molecules residing in 
protected regions are not cleaved. The size restricted cleaving 
agent can be of similar size or larger than any proteins or 
molecules that are to be excluded from the protected region 
Support. 
Activity of the size-restricted cleaving agent can also be 
modulated through control of a number of variables. Relevant 
variables that can be manipulated to control cleaving agent 
activity include, but are not limited to, temperature, pH, ionic 
strength, concentration of any required cations or anions, 
concentration of any required cofactors, time of treatment, 
and/or various combinations of these variables. Time of treat 
ment with the size restricted cleaving agent can affect the 
amount of ligand binding agent molecules remaining on the 
support. For example, FIG. 5 shows the effect of time on the 
amount of antibody remaining after treatment using an anti 
body as the ligand binding agent molecule and papain as the 
size restricted cleaving agent. 
To perform the cleavage treatment, the Support is treated 
with a solution comprising a size restricted cleaving agent. 
The cleavage treatment can be stopped by removal of the 
cleavage agent and/or by addition of an inhibitor. Inhibitors 
can be cysteine protease inhibitors, serine protease inhibitors, 
threonine protease inhibitors, aspartic protease inhibitors, 
metalloprotease inhibitors. For example, iodoacetamide can 
be used to stop the cleavage treatment with papain. Soybean 
trypsin inhibitor, lima bean trypsin inhibitor, Kunitz inhibitor, 
serum trypsin inhibitor, and ovomucoid trypsin inhibitor, for 
example, can be used to stop the cleavage treatment with 
trypsin. Pepstatin can be used to stop the cleavage treatment 
with pepsin. Additional cleaving agent inhibitors will be 
readily recognized by those skilled in the art. The cleavage 
treatment can also be stopped by washing the Support with 
phosphate buffered saline and water to remove the cleavage 
agent and any fragments of the ligand binding agent molecule 
that are cleaved from the support. 
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The size of the protected region can vary if exclusion of 
Smaller or larger sample components is desired. When the 
ligand binding agent molecule is an IgG antibody, for 
example, the size of the protected region of the Support can be 
about 50 A to about 500 A and preferably is about 100 A to 
about 300 A. FIG. 4 shows the effect of pore size on the total 
amount of covalently linked IgG using porous silica as the 
Support. The total amount of bound IgG increased when pore 
size increased from 50 A to 300A and decreased between 300 
A and 500 A. FIG. 4(b) further indicates in examples using 
porous silica that pore size can affect accessibility by the 
cleaving agent. 
The resulting RAM comprising protected covalently 
linked ligand binding agents can be used in a variety of 
applications that provide for target molecule purification or 
target molecule analysis. It is believed that this RAM com 
prising protected covalently linked ligand binding agents can 
be used for analytical chromatography, column chromato 
graph, batch chromatography, or biosensors. 
Restricted Access Medium comprising Unbound Ligand 
Binding Agents or Enzymes in Protected Regions 
Other embodiments of the invention provided herein are 
restricted access media comprising a Support wherein a plu 
rality of protected regions of the Support contain one or more 
unbound ligand binding agent(s) or enzyme molecules and 
wherein the ligand binding agent(s) or enzyme molecule(s) 
are retained in the protected regions by a capping agent. The 
protected region of the Support can be on a Surface, in a pore, 
or a combination of Surfaces and pores. The Support can be 
any support familiar to those skilled in the art that can be used 
directly or in a modified form for ligand binding agent attach 
ment and combinations thereof. The support can be, for 
example, inorganic Support materials. Inorganic Support 
materials can be, for example, silica, glass, alumina, Zirconia, 
silver, and gold. The Support also can be biological Support 
materials. Biological Support materials can be, for example, 
agarose, dextran, and cellulose. The Support further can be 
organic Support materials and organic polymer Supports. 
Organic Support materials and organic polymer Supports can 
be, for example, polystyrene, polymethacrylate, and polya 
mide. The Support can be composite Supports. Composite 
Supports can be, for example, agarose coating on quartz, 
agarose coating on stainless steel, and coated polystyrene? 
divinylbenzene. Modified supports can be, for example, 
silica, glass beads, polystyrene, gold, or silver that contain, 
for example, Surface diol groups, aldehyde groups, hydrazide 
groups, amine groups, and Sulfhydryl groups. Formats for the 
Support can comprise porous or non-porous particles, planar 
surfaces, or flow-through supports. Other formats for the 
Support can include, but are not limited to, monolithic mate 
rials or perfusion Supports, membrane Supports, capillaries, 
fibers, and expanded bed supports. The unbound ligand bind 
ing agent can be a protein, a glycoprotein, a DNA, a RNA, a 
nucleoprotein, a carbohydrate-containing agent, a lipopro 
tein, or related agents. The DNA-based or RNA-based ligand 
binding agent can be an aptamer. Enzymes used in the RAM 
include, but are not limited to, glucose oxidase, horseradish 
peroxidase, and other enzymes that act on Small Substrates 
that can enter and leave the protected regions. Other enzymes 
used in the RAM can include, but are not limited to, that 
oxidoreductases, transferases, hydrolases, lyases, 
isomerases, and ligases. The capping agent can be a glyco 
protein, a glycolipid, a carbohydrate-containing agent, or a 
combination of different capping agents. Related agents 
include, but are not limited to, a protein-protein complex, a 
protein-DNA complex, and a protein-RNA complex. Carbo 
hydrate-containing agents include, but are not limited to, 
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polysaccharides. Polysaccharides can include, but are not 
limited to, glycogen, dextran, agarose, and cellulose. 
RAM provided herein thus comprise media where a ligand 
binding agent or enzyme is retained in a protected region in an 
unbound form. Without seeking to be limited by theory, RAM 
comprising unbound ligand binding agents or enzymes pro 
vide for presentation of the ligand binding agents or enzymes 
in a native or near-native form. In contrast, covalent linkage of 
a ligand binding agent to a Support may decrease ligand 
binding agent activity and/or ligand binding agent specificity. 
Similarly, covalent linkage of an enzyme to a Support may 
decrease enzymatic activity. Moreover, an unbound ligand 
binding agent or enzyme will respectively encounter a target 
molecule or Substrate at a faster rate than a bound ligand 
binding agent or enzyme. 
Method for Preparing Restricted Access Medium comprising 
Unbound Ligand Binding Agents or Enzymes in Protected 
Regions 
Various methods for preparing Restricted Access Medium 
comprising unbound ligand binding agents or enzymes in 
protected regions are provided herein. In certain embodi 
ments, methods for preparing a restricted access media com 
prising incubating an activated Support with a solution com 
prising i) a ligand binding agent or an enzyme molecule and 
ii) an activated capping agent; and removing unbound cap 
ping agent from the incubated Support, thereby preparing the 
restricted access media comprising a Support wherein a plu 
rality of protected regions of the Support contain one or more 
unbound ligand binding agent(s) or enzyme molecule(s) and 
wherein the ligand binding agent(s) or enzyme molecule(s) 
are retained in the protected regions by the capping agent are 
provided. 
Methods provided herein can further comprise washing the 
restricted access media with a solution to deactivate bound 
capping agent. Solutions to deactivate bound capping agent 
include, but are not limited to, a hydrazide-containing agent, 
an amine-containing agent, and a hydrazine-containing 
agent. For example, the hydrazide-containing agent oramine 
containing agent can be oxalic dihydrazide adipic dihy 
drazide, Succinic dihydrazide, ethanolamine, and ethylamine. 
The activated Support can be any support that can be used 
directly or in a modified form for ligand binding agent attach 
ment and combinations thereof. In certain embodiments, acti 
vated Supports can comprise inorganic Support materials. 
Inorganic Support materials can include, but are not limited 
to, silica, glass, alumina, Zirconia, silver, and gold. In certain 
embodiments, activated Supports can comprise biological 
Support materials. Biological Support materials can include, 
but are not limited to, agarose, dextran, and cellulose. Acti 
vated Supports can comprise one or more organic Support 
material(s) and organic polymer Supports. Organic Support 
materials and organic polymer Supports can include, but are 
not limited to, polystyrene, polymethacrylate, and/or polya 
mide. In other embodiments, the activated Support can com 
prise composite Supports. Composite Supports include, but 
are not limited to, an agarose coating on quartz, an agarose 
coating on stainless steel, and coated polystyrene? divinylben 
Zene. In other embodiments, the activated Support can com 
prise modified Supports. Modified supports can include, but 
are not limited to, silica, glass beads, polystyrene, gold, or 
silver that contain an added chemical group. Chemical groups 
used in modified Supports include, but are not limited to, 
Surface diol groups, aldehyde groups, hydrazide groups, 
amine groups, and Sulfhydryl groups. The hydrazide group, 
an amine group, an aldehyde group, or a combination of 
hydrazide groups, amine groups, and/or aldehyde groups of 
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the activated Support can be activated to permit covalent 
binding of a ligand binding agent or linking agent. 
The unbound ligand binding agentorenzyme molecule can 
be a protein, a glycoprotein, a DNA, a RNA, a nucleoprotein, 
a carbohydrate containing agent, a lipoprotein, or related 
agents. Related agents include, but are not limited to, a pro 
tein-protein complex, a protein-DNA complex, and a protein 
RNA complex. The unbound ligand binding agent or enzyme 
molecule and activated capping agent can be incubated 
together or separately with the activated Support. 
The activated capping agent can be a glycoprotein, a gly 
colipid, or a carbohydrate-containing agent. Carbohydrate 
containing agents include, but are not limited to, polysaccha 
rides. Polysaccharides include, but are not limited to, 
glycogen, dextran, agarose, and cellulose. The activated cap 
ping agent can be activated by oxidization with an oxidizing 
agent. Oxidizing agents can include, but are not limited to, 
periodate, a periodate-related chemical, or an enzyme treat 
ment. The periodate can include, but is not limited to, Sodium 
periodate, potassium periodate, or periodic acid. The acti 
vated capping agent can be an oxidized capping agent. For 
example, the oxidized capping agent can be an oxidized gly 
coprotein, a oxidized glycolipid, or an oxidized carbohy 
drate-containing agent. Oxidized carbohydrate-containing 
agents include, but are not limited to, oxidized glycogen, 
oxidized dextran, oxidized agarose, or oxidized cellulose. 
Without seeking to be limited by theory, when the oxidized 
capping agent is incubated with the activated Support, groups 
of the oxidized capping agent such as aldehyde groups, form 
covalent bonds with groups of the Support such as hydrazide 
groups. Thus, the capping agent retains the ligand binding 
agent or enzyme molecule(s) present in the reaction mixture. 
FIG. 9 is an illustration showing retention of a protein using 
oxidized glycogen as the capping agent and a hydrazide 
activated Support. 
After retaining the ligand binding agent or enzyme mol 
ecule(s), the resulting restricted access media can be used for 
measuring the activity of the retained ligand binding agent or 
enzyme molecule(s) and/or placed into columns for uses Such 
as high performance affinity chromatography, Solid-phase 
immunoassays, and immobilized enzyme reactors. 
The resulting RAM comprising protected unbound ligand 
binding agents can be used in a variety of applications that 
provide for target molecule purification or target molecule 
analysis. It is believed that this RAM comprising protected 
unbound ligand binding agents can be used for analytical 
chromatography, column chromatography, batch chromatog 
raphy, or biosensors. 
The resulting RAM comprising protected unbound 
enzymes can be used in a variety of applications that provide 
for conversion of substrates to products. These applications of 
RAM comprising protected unbound enzymes include both 
analytic and preparative uses. It is anticipated that this RAM 
comprising protected unbound enzymes are especially useful 
in applications where it is desirable to sequester the enzyme 
from the sample containing the Substrate. 
Kits for Preparing a Restricted Access Media 
Other embodiments of the invention are kits for preparing 
a restricted access media comprising: i) a Support that is 
Substantially free of ligand binding agent molecules and ii) a 
size restricted cleaving agent. The kits can further comprise 
instructions for using the kit. The kits can also comprise an 
activated Support or an unactivated Support. The kits can also 
comprise a solution for activating the Support. The kits can 
further comprise a ligand binding agent, a linking agent, 
and/or an enzyme molecule that is not covalently linked to the 
Support. The restricted access media that is prepared using the 
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kits can comprise a Support wherein a plurality of protected 
regions of the Support contain one or more covalently linked 
ligand binding agent molecules and wherein a plurality of 
unprotected regions of the Support contain one or more 
covalently linked blocking agent molecule(s). 
In other embodiments, kits comprising a restricted access 
media comprising: i) a Support wherein a plurality of pro 
tected regions of the Support contain one or more covalently 
linked ligand binding agent molecules and whereina plurality 
of unprotected regions of the Support contain one or more 
covalently linked blocking agent molecule(s) and ii) at least 
one container are provided. The kits can further comprise 
instructions for using the kit. 
In still other embodiments of the invention, kits for prepar 
ing a restricted access media comprising: i) a Support that is 
Substantially free of ligand binding agent or enzyme mol 
ecules, and ii) a capping agent are provided. The kits can 
further comprise a solution for activating the capping agent. 
The kits can further comprise a solution for activating the 
support. The kits can further comprise instructions for their 
use. The kits can comprise an activated Support. The kits can 
further comprise a ligand binding agent or an enzyme mol 
ecule that is not associated with the Support. Restricted access 
media that is prepared from the kit can comprise a Support 
wherein a plurality of protected regions of the Support contain 
one or more unbound ligand binding agent(s) or enzyme 
molecule(s) and wherein the ligand binding agent(s) or 
enzyme molecule(s) are retained in the protected regions by a 
capping agent. 
Other embodiments of the invention are kits comprising a 
restricted access media comprising: i) a Support wherein a 
plurality of protected regions of the support contain one or 
more unbound ligand binding agent or enzyme molecules and 
wherein the ligand binding agent(s) or enzyme molecules are 
retained in the protected regions by a capping agent, and ii) at 
least one container. The kits can further comprise instructions 
for using the kit. 
EXAMPLES 
The following examples describe embodiments of the 
invention. Other embodiments within the scope of the claims 
herein will be apparent to one skilled in the art from consid 
eration of the specification or practice of the invention as 
disclosed herein. It is intended that the specification, together 
with the examples, be considered exemplary only, with the 
Scope and spirit of the invention being indicated by the claims 
which follow the examples. 
Example 1 
Description of Chemicals and Apparatus 
Nucleosil Si-50, Si-100, Si-300 and Si-500 silica supports 
(7 um particle diameter; nominal pore size, 50, 100, 300 or 
500 A, respectively) were from Macherey Nagel (Düren, 
Germany). Rabbit immunoglobulin G (IgG, reagent grade), 
monoclonal anti-fluorescein antibodies (anti-FITC clone FL 
D6, produced in mouse ascites fluid), the fluorescein conju 
gate of bovine serum albumin (fluorescein-BSA; prepared 
using fluorescein isothiocyanate and giving 12 mol fluores 
cein/mol protein), papain (85% protein, from papaya latex), 
fluorescein (290% pure), periodic acid reagent (>99% pure), 
sodium cyanoborohydride (>99% pure), sodium borohydride 
(98% pure), D/L-dithiothreitol (DTT, >99% pure), iodoaceta 
mide (-99% pure), and ethylenediaminetetraacetic acid diso 
dium salt dehydrate (EDTA, -99% pure) were from Sigma 
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(St. Louis, Mo.). The 3-glycidoxypropyltrimethoxysilane 
(>94% pure), and oxalic dihydrazide (98% pure) were from 
Aldrich (Milwaukee, Wis.). Ethylene glycol (>99% pure) was 
from Fisher Scientific (Pittsburgh, Pa.). The acetic acid 
(>99.7% pure) was from EMD chemicals (Gibbstown, N.J.). 
Reagents for the bicinchoninic acid (BCA) protein assay 
were from Pierce (Rockford, Ill.). All aqueous solutions were 
prepared using water from a Nanopure system (Barnstead, 
Dubuque, Iowa) and were filtered using 0.22 um nylon filters 
(Fisher Scientific). 
Slide-A-Lyzer dialysis cassettes (7 kDa MW cutoff, 0.5-3 
mL capacity) were from Pierce. BCA assays were performed 
using a Shimadzu UV-160A spectrophotometer (Kyoto, 
Japan). Fluorescence spectra were acquired with a Shimadzu 
RF-5301 PC spectrofluorometer using the following settings: 
excitation wavelength, 460 nmi; emission wavelengths, 300 
700 nm, slit width, 3.0 nm for both excitation and emission; 
scan speed, medium; sensitivity, high. The buffers employed 
in preparing samples were used to autoZero the spectrofluo 
rometer before each analysis. 
The RAM prepared using IgG antibody as the ligand bind 
ing agent molecule and control columns were packed using a 
Shimadzu LC-10AT pump and a Rheodyne 710 six-port valve 
(Cotati, Calif.). The chromatographic system comprised a 
Perkin Elmer Series 200 micropump (Norfolk, Conn.) and a 
Shimadzu RF-525 fluorescence detector. Samples were 
injected using a Rheodyne LabPro valve equipped with a 200 
LL loop. Chromatographic data were collected and processed 
using LabView 5.1 (National Instruments, Austin, Tex.). 
Example 2 
Preparation of Aldehyde-Activated Support 
A silica Support was converted into a diol form by treating 
a 500 mg quantity of the Support with 3-glycidoxypropyltri 
methoxysilane to introduce epoxy groups onto the silica. The 
resulting epoxy silica support was treated with 0.1 M sodium 
acetate buffer at pH 5.5 by sonication under vacuum for 10-15 
minutes. 3-Glycidoxypropyltrimethoxysilane (5%-10% V/v) 
was added into the suspension and shaken for 5 hours at 90° 
C. The epoxy silica support was washed several times with 
water and an aqueous solution of sulfuric acid (pH 3.0). The 
epoxy silica support was then suspended in 100-150 mL of an 
aqueous sulfuric acid solution (pH 3.0) and refluxed for one 
hour to convert the epoxy silica support into a diol form. The 
resulting diol silica Support was washed with several portions 
of water, methanol and ether. The diol silica support was dried 
overnight under vacuum and stored in a desiccator until use. 
The diol content of the diol silica support was determined 
using an iodometric capillary electrophoresis assay. 
To convert the diol groups to aldehyde groups, 500 mg of 
the diol silica support was suspended in 10 mL of a 90% (v/v) 
mixture of acetic acid and water that contained 500 mg peri 
odic acid. The mixture was sonicated under vacuum for 20 
minutes and shaken on a wrist-action shaker for 2 hours at 
room temperature. The resulting aldehyde-activated silica 
was washed several times with water and, 0.10M potassium 
phosphate buffer (pH 6.0). The aldehyde-activated silica Sup 
port was used directly for preparing a restricted access media 
or for preparing a hydrazide-activated silica Support. 
Example 3 
Preparation of Hydrazide-Activated Support 
To prepare a hydrazide-activated silica Support, 200 mg of 
the aldehyde-activated silica support was suspended in 30 mL 
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of 0.10M potassium phosphate buffer (pH 5.0) that contained 
a 5-fold mole excess of oxalic dihydrazide versus the initial 
diol groups present in the added aldehyde-activated silica 
Support. The slurry was shaken for 2 hours at room tempera 
ture on a wrist-action shaker. The Support was then washed 
several times with 0.10 M potassium phosphate buffer (pH 
7.0). After activation, a 25-fold mol excess of sodium boro 
hydride (versus the initial diol groups) in 4 mL of 0.10 M 
potassium phosphate buffer (pH 8.0) was added in several 
Small portions to the Support slurry to reduce any remaining 
aldehyde groups. This mixture was shaken for 90 minutes at 
room temperature and washed several times with 0.10 M 
potassium phosphate buffer (pH 7.0). The final hydrazide 
activated support was stored in 0.10M potassium phosphate 
buffer (pH 7.0) at 4°C. until use. 
Example 4 
Preparation of RAM Using IgG Antibody Covalently 
Linked According to an Aldehyde-Activation (Schiff 
Base) Method 
Rabbit IgG was used without pretreatment. A 13 mg/mL 
slurry of aldehyde-activated silica (prepared as described in 
Example 2) was sonicated under vacuum for 5 minutes in 0.10 
M potassium phosphate buffer (pH 6.0). To this slurry was 
added 0.69, 0.69, 0.20 or 0.069 mg antibody per mg of alde 
hyde-activated Nucleosil Si-50, Si-100, Si-300 or Si-500 
silica, respectively. Rabbit IgG amounts were at least two 
fold greater than the maximum amount that could be immo 
bilized to the surface of each support, as determined by Kim 
et al., (In Handbook of Afinity Chromatography, Hage, D. S., 
ed. CRC Press: Boca Raton, Fla. (2006)) and calculations 
based on the known Surface area of these Supports and the size 
of IgG (see, Walters et al. (140 Anal. Biochem. 190-195 
(1984)). About 8 mg/mL sodium cyanoborohydride was also 
added to each reaction slurry to promote the formation of 
stable secondary amine linkages between the retained anti 
bodies and the support. The slurry was shaken for 3 days at 4 
C. The resulting material was washed several times with 0.10 
Mpotassium phosphate buffer (pH 8.0). The support was then 
Suspended in 2 mL of a 4 mg/mL Solution of sodium borohy 
dride in 0.10 M potassium phosphate buffer pH (8.0) to con 
Vert any remaining aldehyde groups into alcohols. The mix 
ture was shaken for 90 minutes at room temperature. The 
resulting antibody restricted access medium was washed sev 
eral times with water for later use in a BCA assay or dried 
overnight under vacuum and stored in a desiccator for later 
analysis. 
Example 5 
Preparation of RAM Using IgG and Anti-Fluorescein 
Antibodies Covalently Linked According to a 
Hydrazide-Activation (Site-Selective) Method 
Rabbit IgG and anti-fluorescein (monoclonal anti-FITC 
clone FL-D6) antibodies to be covalently linked using the 
hydrazide-activation method were oxidized with periodate to 
generate aldehyde groups in their carbohydrate regions. To 
oxidize rabbit IgG, 2 mg/mL of rabbit IgG was added to a 
solution containing 20 mM sodium acetate and 0.15 M 
sodium chloride (pH 5.5). To oxidize anti-fluorescein anti 
bodies, the anti-fluorescein antibodies were exchanged into 
20 mM sodium acetate and 0.15 M sodium chloride (pH 5.5) 
buffer using Econo-Pac 10 DG desalting columns (BioRad; 
Hercules, Calif.) at about 2 mg/mL final concentration. A 20 
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mM solution of periodic acid was made in the same buffer (20 
mM sodium acetate containing 0.15 M sodium chloride, pH 
5.5) and added to the antibody solutions in a 1:1 volume ratio. 
The mixtures were protected from light exposure by wrap 
ping the containers in aluminum foil and shaken for 30 min 
utes at room temperature. The oxidation process was 
quenched by adding 0.25 mL of ethylene glycol per mL of the 
oxidized antibody solution and shaking an additional 5 min 
utes at room temperature. Excess periodic acid was removed 
from the oxidized antibody solution by dialysis in two hour 
cycles against one 2 L portion of 20 mM sodium acetate and 
0.15 M sodium chloride (pH 5.5) and three 2 L portions of 
0.10 potassium phosphate buffer (pH 7.0). The final oxidized 
antibody solution was passed through a 0.22 Lum filter to 
remove any cross-linked or precipitated immunoglobulins. 
The concentrations of the final antibody solutions were deter 
mined to be 0.6-0.7 mg/mL by a BCA assay. Oxidized anti 
body was combined with 4-5 mg hydrazide-activated silica 
Supporting antibody and incubated in 0.10M potassium phos 
phate buffer (pH 7.0) at 4°C. for 3 days. The supernatant was 
collected and analyzed by a BCA assay. The Support contain 
ing the covalently linked antibody was packed within a col 
umn or washed several times with water and dried overnight 
under vacuum for analysis by a BCA assay. 
Example 6 
Preparation of Immunoaffinity-Restricted Access 
Media 
RAM prepared in Examples 4 and 5 were treated with a 
size restricted cleaving agent to prepare immunoaffinity 
restricted access media (“IA-RAM). In this example, papain 
was used as the size restricted cleaving agent. The papain 
Solution comprised 2 mg/mL papain in phosphate-buffered 
saline (PBS; pH 7.5) containing 50 mM phosphate, 150 mM 
sodium chloride, 2.7 mM potassium chloride, 2 mM EDTA 
and 1 mM DTT. DTT was used to reduce disulfide bonds 
within papain for activation. 
To perform the papain cleavage treatment, the desired 
immunoaffinity Support (either aldehyde-activation method 
or hydrazide-activation method) was washed twice with the 
PBS (pH 7.5), suspended in PBS (pH 7.5) and sonicated for 5 
minutes. The concentration of antibodies in the Solution was 
0.3-1.2 mg/mL. The papain solution was added to the slurry at 
a papain:immunoglobulin ratio of 1:100 (w/w). The mixture 
was incubated at 37°C. for 30 minutes. The papain treatment 
was stopped by adding 30 mMiodoacetamide and incubating 
in the dark for 60 minutes on ice. The papain-treated support 
was washed several times with PBS and water to remove the 
papain and any antibody fragments cleaved from the Support. 
Supports to be examined by a BCA assay were dried over 
night under vacuum and stored in a desiccator at room tem 
perature. The anti-fluorescein support to be used in chromato 
graphic studies was washed three times with 0.10 M 
potassium phosphate buffer (pH 7.4) and stored in this buffer 
at 4°C. until use. 
The anti-fluorescein IA-RAM support was packed into a 
sandwich microcolumn according to Clark et al., (73 Anal. 
Chem. 2157-2164 (2001)) and Clarke et al., (73 Anal. Chem. 
1366-1373 (2001)). The column had an inner diameter of 2.1 
mm and a total length of 1.0 cm, with a 2 mm long section in 
the middle containing the anti-fluorescein IA-RAM support 
while the remainder contained an inert layer of diol silica. The 
Support was placed into the column by making fifty-three 
200-uI, injections of a 0.32 mg/mL slurry of the anti-fluores 
cein IA-RAM supportin 0.067 M potassium phosphate buffer 
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(pH 7.0). A 2 mg/mL slurry of diol Nucleosil Si-100 in 0.067 
M potassium phosphate buffer (pH 7.0) was used to fill the 
remainder of the column. A control column was prepared in a 
similar manner using diol silica in place of the IA-RAM 
Support. 
Example 7 
Evaluation of IA-RAM Supports 
The amount of polypeptides on an IA-RAM support before 
or after treatment with papain was determined using a BCA 
assay. The amount of antibodies/IgG placed on a Support by 
the hydrazide-activation (site-selective) method was deter 
mined by comparing the final and initial concentrations of the 
antibodies/IgG in the Supernatant of the reaction slurry and/or 
by directly measuring the final protein content of the Support. 
The amount of antibodies/IgG remaining after papain treat 
ment was determined by comparing the protein content of the 
Support before and after papain treatment. 
The binding properties of the anti-fluorescein IA-RAM 
support were initially determined before and after digestion 
by reacting this Support with a known excess of fluorescein 
(sodium salt, MW=376 Da) or fluorescein-BSA conjugate 
(average MW-69.5 kDa). Studies were performed using anti 
fluorescein antibodies covalently linked to Nucleosil Si-100 
using the hydrazide-activation method. A 2 mg portion of the 
desired anti-fluorescein Support was incubated with shaking 
in 1 mL of a 0.040 ug/mL fluorescein solution or 1 mL of 20 
ug/mL fluorescein-BSA solution in 0.1 M potassium phos 
phate buffer (pH 7.4) at 4°C. for 30 minutes. The mixtures 
were centrifuged and the Supernatant was analyzed for fluo 
rescein or fluorescein-BSA content based on the fluorescence 
of the solutions. Standard solutions that contained 0.002-2.0 
ug/mL fluorescein or 1-30 ug/mL of the fluorescein-BSA 
conjugate in 0.10 M potassium phosphate buffer (pH 7.4) 
were also analyzed. The amount of fluorescein or fluorescein 
BSA bound to the anti-fluorescein IA-RAM supports was 
determined by comparing the final and initial concentrations 
of fluorescein or fluorescein-BSA that remained in solution. 
For chromatographic Studies, 200LL injections of samples 
containing 0.5 nM fluorescein or 3 nM of fluorescein-BSA 
were made at flow rates ranging from 0.1-1.0 mL/min. The 
injections were performed at room temperature using 0.067 
M potassium phosphate buffer (pH 7.4) as the application 
buffer. Two or three replicate injections were made at each 
flow rate onto columns containing the anti-fluorescein IA 
RAM Support or the corresponding control Support. The 
amount of non-retained fluorescein or fluorescein-BSA was 
monitored using an on-line fluorescence detector set at exci 
tation and emission wavelengths of 488 and 520 nm, respec 
tively. The fraction of extracted fluorescein was calculated by 
comparing the areas of the non-retained peaks to those 
obtained using a control column. Measurements made at 0.01 
mL/min (i.e., an incubation time 10-fold longer than the 
longest sample contact time used in the extraction study) were 
used to correct the peak areas for any Small amount of non 
binding, fluorescent contaminants that were present in the 
samples. The retained species were eluted between studies by 
washing the column with a 0.067 M potassium phosphate 
buffer (pH 2.5) for 20 minutes. Elution was followed by a 
column regeneration step by applying 0.067 M phosphate 
application buffer (pH 7.4) for 10 minutes before each new 
sample injection. 
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Example 8 
Effect of Cleaving Agent Treatment Time 
FIG. 5 shows the results of varying the treatment time of 
the cleaving agent. Rabbit IgG was covalently linked accord 
ing to the aldehyde-activation (i.e., Schiffbase) method onto 
a 100 A pore size silica support and treated with papain as the 
cleaving agent. Antibodies covalently linked to this Support 
were treated using an initial papain:antibody ratio of 1:100 
(w/w), but the treatment time ranged from 0 to 6 hours. 
As shown in FIG. 5, a sharp decrease in the amount of 
antibody remained on the Support as the treatment time with 
papain increased from 0 to 30 minutes. At 30 minutes, the 
total antibody content had decreased to 36 (t2) mg/g Support, 
which was 62 (+6)% of the antibody content before treatment. 
As the treatment time continued, however, the amount of 
antibody remaining on the Support decreased only slightly 
and approached a fixed value. These results indicate that all of 
the accessible antibodies on the support had been cleaved by 
papain. Similar results were observed in experiments using 
300 A pore size silica supports. 
Example 9 
Effect of Cleaving Agent Concentration 
The concentration of cleaving agent added to the Support 
for treatment (as reflected by the cleaving agent:antibody 
ratio) can also control the amount of F, regions remaining on 
the IA-RAM support after cleaving agent treatment. Without 
being held to a particular theory, a low concentration of cleav 
ing agent may lead to slow or incomplete digestion of anti 
bodies while higher concentrations may lead to aggregation 
or adsorption onto the Support. The effect of varying cleaving 
agent:antibody ratio was examined using rabbit IgG that was 
covalently linked using the hydrazide-activated Support 
method onto a 100 A pore size silica support and treated with 
papain for 3 hours. In this study the concentration of papain 
used for digestion was varied from a papain:antibody ratio of 
1:400 to 1:10 (w/w). 
FIG. 6 shows a sharp decrease in the amount of antibody 
left on IA-RAM supports after treatment with papain using 
papain:antibody ratios of 1:400 to 1:100, or 0.0025 to 0.010 
papain:IgG (w/w). Similar antibody contents were observed 
after treatment of Supports using larger papain:antibody 
ratios of 1:50-1:10, or 0.020-0.10 papain:IgG (w/w). There 
fore, most of the accessible antibodies were cleaved by papain 
within 3 hours using an papain:antibody ratio of 1:100 or 
greater. 
Example 10 
Effect of Method for Covalently Linking IgG 
Antibody 
The effect of the method for covalently linking the anti 
body was examined by covalently linking rabbit IgG using an 
aldehyde-activated silica support (Schiff base) method or a 
hydrazide-activated silica Support method. Supports with a 
pore size of 100 A were treated with papain for 3 hours using 
an papain:antibody ratio of 1:100. In the aldehyde-activated 
silica support (Schiff base) method, the polypeptide content 
of the support before and after treatment with papain was 58 
(t4) or 33 (t2) mg/g silica, respectively. 
In the hydrazide-activated Support method, the polypeptide 
content of the support before and after treatment with papain 
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was 98 (ta) and 47 (+2) mg/g silica, respectively. The original 
amount of covalently linked antibodies following the 
hydrazide-activated Support method was 1.6-fold larger than 
that obtained by the aldehyde-activated silica support (Schiff 
base) method, while the amount of antibodies remaining after 
treatment with papain was 1.4-fold larger. The larger amount 
of covalently linked antibodies in the hydrazide-activated 
Support method compared to the aldehyde-activated silica 
support (Schiffbase) method has been observed and may be 
related to the more uniform orientation of antibodies in the 
hydrazide-activated Support method. (See e.g., Clarke et al., 
(888.J. Chromatog. 13-22 (2000)). This difference compared 
to the aldehyde-activated silica support (Schiffbase) method 
may also reflect the more ordered orientation of antibodies in 
the hydrazide-activated support method, which could have 
made more F, regions accessible to papain for cleavage. 
Without being limited by theory, however, these results may 
vary with the type of antibody used. For example, anti-fluo 
rescein mouse monoclonal antibodies retained by the 
hydrazide-activated support method gave a 53% recovery of 
activity after treatment with papain, which is similar to the 
results noted in this section for rabbit IgG when using the 
aldehyde-activated silica support (Schiffbase) method. Thus, 
the method of covalently linking the antibody may affect the 
preparation of the RAM. 
The overall binding capacity of the support may further 
depend on the activity of the covalently linked antibodies 
along with the total antibody content and fraction of F, 
regions present on the final material. For example, if there is 
about a 50% retention of activity for F, regions in the alde 
hyde-activated silica support (Schiffbase) method, the result 
ing binding capacity for a RAM can be about 110 nmol/g 
silica for a low mass target. If 85-100% retention of activity 
occurs in the hydrazide-activated Support method, the result 
ing binding capacity for a RAM can be about 104-122 nmol/g 
silica for a low mass target even though fewer F, regions are 
present in the final material. Therefore, slightly different val 
ues may be obtained for other types of antibodies or when 
using alternative methods for covalently linking the ligand 
binding agent molecule. 
Example 11 
RAM in Static Binding 
Fluorescein and a fluorescein-BSA conjugate were used as 
low mass and high mass target to evaluate the binding and 
selectivity of a RAM prepared using covalently linked anti 
fluorescein antibodies. Fluorescein was useful as a model for 
drugs or other low mass solutes because of its size (MW. 376 
Da), its ease of detection, and the availability of monoclonal 
anti-fluorescein antibodies. Fluorescein-BSA (MW, 69.5 
kDa) was valuable as a model for a high mass target because 
both BSA and its human counterpart HSA (MW, 66.5 kDa) 
bind to a variety of drugs, hormones and other Small solutes. 
Anti-fluorescein antibodies were covalently linked to a 
silica support with a pore size of 100 A by the hydrazide 
activated Support method. A portion of this Support was set 
aside for use as a reference while the remainder was treated 
with papain for 90 minutes at 37°C. using an cleaving agent: 
antibody ratio of 1:100 (w/w). The resulting RAM was 
washed with PBS buffer to remove the cleaving agent and any 
F, fragments cleaved from the antibodies. Known amounts 
of the treated and original anti-fluorescein RAM were incu 
bated for 30 minutes with an excess of fluorescein or fluores 
cein-BSA conjugate to saturate any accessible binding 
regions for these targets on the Support. The fluorescein or 
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fluorescein-BSA that was bound by anti-fluorescein antibod 
ies was determined by determining the amount of the analytes 
that remained in Solution after the incubation step. 
The original binding capacity of the covalently linked anti 
bodies was estimated using this approach to be 0.97 (+0.02) 
ug/g silica for fluorescein or 0.69 (+0.01) mg/g silica for the 
fluorescein-BSA conjugate. It was also found that the binding 
capacity for fluorescein-BSA decreased by 92% (+3)% for 
the anti-fluorescein support after treatment with papain. 
However, the binding capacity for fluorescein decreased by 
only 47 (+2)%. These results indicated that the treated Sup 
port was more selective in binding to a low mass target Such 
as fluorescein and gained some size selectivity, as would be 
predicted for a RAM material. 
Example 12 
RAM for Ultrafast Extraction 
The RAM, specifically an IA-RAM made using anti-fluo 
rescein antibody, was tested for use in a flow-based system for 
the selective, ultrafast extraction of fluorescein versus a fluo 
rescein-BSA conjugate. This was accomplished by compar 
ing the results obtained with a RAM column to results for a 
control column containing only diol silica. The amount of 
injected fluorescein or fluorescein-BSA in these studies was 
1.5% or 20% of the total binding capacity for these two 
analytes on the RAM support. 
FIGS. 7(a) and (b) show chromatograms obtained when 
fluorescein or fluorescein-BSA were injected at 0.1 mL/min 
onto the anti-fluorescein RAM column and a control column 
with no antibodies present. The fluorescein was quantita 
tively extracted by the RAM column but gave no signs of 
retention on the control column under the same conditions. 
When the same experiment was performed with fluorescein 
BSA, no significant degree of binding was seen on either the 
RAM column or control column. 
FIG. 8 illustrates how the extent of extraction varied using 
different flow rates and residence times for contact between 
fluorescein or fluorescein-BSA with the anti-fluorescein 
RAM column. It was found that 90% of the fluorescein was 
extracted when using a contact time of 1.2 s and 80% fluo 
rescein was extracted in 0.9s. Although this rate of extraction 
was quite fast, it was slower than what has been noted for the 
same type of antibodies on more traditional silica-based 
immunoaffinity supports that have not been treated with 
papain. This difference may be due to the decreased amount 
of F, regions present in the anti-fluorescein RAM Support 
Versus these other materials. Under the same conditions used 
for fluorescein, less than 1% of the fluorescein-BSA conju 
gate was extracted by the anti-fluorescein RAM support. 
Thus, a RAM support may be quite selective for a low mass 
Versus high mass target when used under these conditions. 
Example 13 
Method for Preparing Restricted Access Media with 
a Protected and Unbound Ligand Binding Agent or 
Enzyme Molecule 
A Nucleosil silica support was converted into a hydrazide 
activated form by treating a 500 mg quantity of the Support 
with 3-glycidoxypropyltrimethoxysilane to introduce epoxy 
groups onto the silica. The resulting epoxy silica Support was 
treated with 0.1 M sodium acetate buffer (pH 5.5) by sonica 
tion under vacuum for 10-15 minutes. 3-Glycidoxypropyltri 
methoxysilane (5%-10% V/v) was added to the suspension 
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and shaken for 5 hours at 90°C. The epoxy silica support was 
washed several times with water and an aqueous Solution of 
sulfuric acid (pH 3.0). The epoxy silica support was then 
suspended in 100-150 mL of an aqueous sulfuric acid solu 
tion (pH 3.0) and refluxed for one hour to convert the epoxy 
silica Support into a diol form. The resulting diol silica Sup 
port was washed with several portions of water, methanol and 
ether. The diol content of the diol silica support was deter 
mined using an iodometric capillary electrophoresis assay. 
The diol silica Support was used to prepare an aldehyde 
activated silica Support. To convert the diol groups to alde 
hyde groups, 500 mg of the diol silica Support was suspended 
in 10 mL of a 90% (v/v) mixture of acetic acid and water that 
contained 500 mg periodic acid. This mixture was sonicated 
under vacuum for 20 minutes and shaken on a wrist-action 
shaker for 2 hours at room temperature. The resulting alde 
hyde-activated silica was washed several times with water 
and, 0.10M potassium phosphate buffer (pH 6.0). A 200 mg 
quantity of the aldehyde-activated silica Support was sus 
pended in 30 mL of 0.10 M potassium phosphate buffer (pH 
5.0) that contained a 5-fold mole excess of oxalic dihydrazide 
Versus the initial diol groups present in the added aldehyde 
activated silica Support. The slurry was shaken for 2 hours at 
room temperature on a wrist-action shaker. The Support was 
then washed several times with 0.10 M potassium phosphate 
buffer (pH 7.0). After activation, a 25-fold mol excess of 
sodium borohydride (versus the initial diol groups) in 4 mL of 
0.10 M potassium phosphate buffer (pH 8.0) was added in 
several Small portions to the Support slurry to reduce any 
remaining aldehyde groups. This mixture was shaken for 90 
minutes at room temperature and washed several times with 
0.10 M potassium phosphate buffer (pH 7.0). The final 
hydrazide-activated support was stored in 0.10 M potassium 
phosphate buffer (pH 7.0) at 4°C. until use. 
Glycogen was oxidized for use as the oxidized polysaccha 
ride by reacting a 5 mg/mL glycogen Solution with a 20 
mg/mL Solution of periodate for 12 hours at room tempera 
ture in a solution containing 20 mM sodium acetate, 0.15 mM 
sodium chloride (pH 7.0). The oxidized glycogen was puri 
fied using an Econo-Pac 10DG disposable column and 0.1 M 
potassium phosphate buffer (pH 5.0). 
Example 14 
Restricted Access Media with Protected and 
Unbound Human Serum Albumin 
A 50 mg/mL human serum albumin (“HSA) solution was 
prepared in the 20 mM sodium acetate, 0.15 mM sodium 
chloride (pH 7.0) solution. A 0.03 g quantity of hydrazide 
activated silica support was mixed with 0.5 mL of the 50 
mg/mL HSA solution and sonicated under vacuum for 15 
minutes. A 100LL quantity of purified oxidized glycogen was 
added to the support-HSA mixture and shaken for 24 hours at 
room temperature. A 0.2 mL. Volume of a 2 mg/mL oxalic 
dihydrazide solution was added during the last hour of the 
reaction to cover any remaining aldehyde groups on the oxi 
dized glycogen. The Support was then washed several times 
with 0.1 M potassium phosphate solution (pH 7.0) and deion 
ized water. Two control Supports were prepared in the same 
manner but with no HSA or no oxidized glycogen added to 
the hydrazide-activated silica. After preparation, the HSA and 
control Supports were placed into separate 50 mmx2.1 mm 
I.D. stainless steel columns using 0.067 M phosphate buffer 
(pH 7.4). 
As shown in FIG. 10, supports with pore sizes below 300 A 
retained more HSA than larger pore size silica (500 A and 
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1000 A). Supports with 50 A pore size had the greatest 
amount of retained HSA. Without being held to a particular 
theory, the size of the glycogen capping agent may prevent it 
from getting into pores Smaller than 300 A, making it easier 
for glycogen to cap Such pores. As the pore size increased, 
glycogen may have entered a greater number of pores, giving 
a much smaller available volume for HSA retention. 
Example 15 
Restricted Access Media with Protected and 
Unbound Alpha 1-Acid Glycoprotein 
A similar process used for obtaining restricted access 
media with protected and unbound HSA was used to obtain 
restricted access media with protected and unbound alpha 
1-acid glycoprotein (AGP). A 25 mg sample of AGP was 
dissolved in 0.5 mL. Volume of a 4.2 mg/mL oxidized glyco 
gen in 0.1 M potassium phosphate buffer (pH 5). The AGP/ 
oxidized glycogen mixture was incubated with 0.15 g of 
hydrazide-activated silica support having 100 A pore size for 
2 days at 4°C. The support was washed several times with 0.1 
M potassium phosphate buffer (pH 7) and packed into a 
10x2.1 mm I.D. stainless steel column using 0.067 M phos 
phate buffer (pH 7.4) as the packing solution. Two control 
supports were prepared in the same manner but with no AGP 
or no oxidized glycogen added to the hydrazide-activated 
silica during the retention step. 
Example 16 
Activity of Protected and Unbound HSA in 
Restricted Access Media 
Restricted access media with protected and unbound HSA 
was examined for HSA activity using S-warfarin, which is 
known to bind HSA. The binding capacities for the protected 
and unbound HSA columns are summarized in Table 1. Using 
the known content of HSA of these supports and the binding 
capacities, the specific activity for the retained HSA was 
determined. See, Table 1. The average specific activity was 91 
(+29)%. This value was statistically equivalent to 100% and 
significantly higher than the specific activity reported for 
covalently immobilized HSA (see, Loun et al. 66Anal. Chem. 
3814-3822 (1994)). Association equilibrium constants also 
were determined for S-warfarin with retained HSA. Results 
are summarized in Table 1. Values ranged between 1.4 and 
2.0x10 M' at pH 7.4 at 37° C. These values were in good 
agreement with those reported for soluble HSA and immobi 
lized HSA (e.g., 2.0x10 M') (see, Loun et al. 66 Anal. 
Chem. 3814-3822 (1994)). 
TABLE 1 
Binding capacity and specific activity for S-warfarin on 
HSA Retained RAM columns. 
Association 
Binding Capacity Equilibrium Constant 
Pore Size (x10 mol) Specific Activity (x10M) 
1000 A 1.3 (+/-0.2) 1.1 (+/-0.2) 2.0 (+/-0.3) 
500 A 1.8 (+/-0.2) 1.29 (+/-0.17) 1.4 (+/-0.2) 
300 A 1.6 (+/-0.2) 0.73 (+/-0.11) 1.5 (+/-0.2) 
100 A 1.8 (+/-0.2) 0.85 (+/-0.11) NA 
50 A 2.1 (+/-0.2) 0.56 (+/-0.11) 1.9 (+/-0.2) 
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The discussion of the references herein is intended merely 
to Summarize the assertions made by their authors and no 
admission is made that any reference constitutes prior art. 
Applicant reserves the right to challenge the accuracy and 
pertinence of the cited references. 
In view of the above, it will be seen that the several advan 
tages of the invention are achieved and other advantageous 
results attained. As various changes could be made in the 
above methods and compositions without departing from the 
Scope of the invention, it is intended that all matter contained 
in the above description and shown in the accompanying 
drawings shall be interpreted as illustrative and not limiting. 
Thus, the breadth and scope of the present invention should 
not be limited by any of the above-described exemplary 
embodiments, but should be defined only in accordance with 
the following claims appended hereto and their equivalents. 
What is claimed is: 
1. A restricted access media comprising a Support wherein 
a plurality of protected regions of said Support contain one or 
more unbound ligand binding agent(s) or enzyme molecules, 
and wherein said unbound ligand binding agent(s) or enzyme 
molecule(s) are retained in said protected regions by a cap 
ping agent that is bound to said Support, and wherein said 
ligand binding agent(s) or enzyme molecule(s) are not bound 
to said Support. 
2. The restricted access media of claim 1, wherein said 
Support comprises an inorganic material, a biological mate 
rial, an organic material, an organic polymer, a composite 
Support, or a modified Support. 
3. The restricted access media of claim 1, wherein said 
unbound ligand binding agent comprises a protein, a glyco 
protein, a DNA, a RNA, a nucleoprotein, a carbohydrate 
containing agent, a lipoprotein, or a combination thereof. 
4. The restricted access media of claim 1, wherein said 
capping agent comprises a glycoprotein, a glycolipid, a car 
bohydrate containing agent, or a combination thereof. 
5. The restricted access media of claim 4, wherein said 
carbohydrate containing agent comprises glycogen, dextran, 
agarose, or cellulose. 
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6. A method for preparing a restricted access media com 
prising: 
a) incubating an activated Support with a solution compris 
ing: i) aligand binding agent oran enzyme molecule and 
ii) an activated capping agent; and 
b) removing unbound capping agent from said incubated 
Support, thereby preparing the restricted access media 
comprising a Support wherein a plurality of protected 
regions of said Support contain one or more unbound 
ligand binding agent(s) or enzyme molecule(s) and 
wherein said unbound ligand binding agent(s) or 
enzyme molecule(s) are retained in said protected 
regions by said capping agent that is bound to said Sup 
port, and wherein said ligand binding agent(s) or 
enzyme molecule(s) are not bound to said Support. 
7. The method of claim 6, wherein said ligand binding 
agent or said enzyme molecule and said activated capping 
agent are incubated together or separately with said activated 
Support. 
8. The method of claim 6, wherein said activated support is 
activated by a hydrazide group, an amine group, an aldehyde 
group, or a combination thereof. 
9. The method of claim 6, wherein said unbound ligand 
binding agent or enzyme molecule comprises a protein, a 
glycoprotein, a DNA, a RNA, a nucleoprotein, a carbohydrate 
containing agent, a lipoprotein, or a combination thereof. 
10. The method of claim 6, wherein said support comprises 
a porous support with a pore size of about 50 A to about 1000 
11. A kit comprising a restricted access media that com 
prises comprising: i) a Support wherein a plurality of pro 
tected regions of said support contain one or more unbound 
ligand binding agent or enzyme molecules, and wherein said 
ligand binding agent(s) or enzyme molecules are retained in 
said protected regions by a capping agent that is bound to said 
Support, and wherein said ligand binding agent(s) or enzyme 
molecule(s) are not bound to said Support, and ii) at least one 
container. 
